Bone Pain Treatment Market Report 2026

The bone pain treatment market size has grown strongly in recent years. It will grow from $6.05 billion in 2025 to $6.5 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to fracture incidence, cancer metastasis to bone, opioid pain management, hospital orthopedic care, aging population.

The bone pain treatment market size is expected to see strong growth in the next few years. It will grow to $8.58 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to opioid regulation, non-pharmacological therapy growth, oncology supportive care expansion, rehabilitation services growth, chronic pain management focus. Major trends in the forecast period include increased use of multimodal pain management, growth of non-opioid pain therapies, expansion of cancer-related bone pain treatment, adoption of physical and rehabilitative therapies, focus on personalized pain management.

The increasing prevalence of osteoporosis is expected to drive the growth of the bone pain treatment market going forward. Osteoporosis is a medical condition characterized by reduced bone density and strength, resulting in fragile bones that are more susceptible to fractures. The condition is rising due to the aging global population, as bone density naturally declines with age, increasing the risk of osteoporosis. Bone pain treatments help manage osteoporosis by alleviating discomfort and improving mobility, supporting overall bone health and enhancing disease management. For instance, in April 2023, according to the AO Foundation, a Switzerland-based nonprofit organization, osteoporotic fractures occur every three seconds worldwide, affecting approximately 8.9 million people annually. In the U.S., these injuries already cost the healthcare system around USD 14 billion annually, with projections suggesting the economic burden could more than double by 2025. Therefore, the increasing prevalence of osteoporosis is driving the growth of the bone pain treatment market.

Major companies in the bone pain treatment market are focusing on developing innovative solutions, such as prescription wearable devices, to deliver targeted pain relief. Prescription wearable devices are medically approved gadgets worn on the body that provide therapies such as electrical stimulation or heat to reduce bone pain by enhancing blood flow, decreasing inflammation, or blocking pain signals. For instance, in May 2025, Osteoboost Health Inc., a US-based medical equipment manufacturer, introduced Osteoboost, the first FDA-cleared wearable device for low bone density. This wearable belt delivers low-amplitude, high-frequency vibration therapy (20-40 Hz) to the spine and hips, aimed at slowing the loss of bone strength in postmenopausal women with osteopenia. Worn for 30 minutes daily during regular activities, the device is clinically proven to reduce the decline in bone strength and volumetric bone density, with no significant adverse events reported. Its design includes a motorized vibration pack, pressure sensor, and accelerometers to ensure safe and effective therapy delivery.

In November 2023, Boston Scientific Corporation, a US-based biotechnology company, acquired Relievant Medsystems Inc. for USD 850 million. This acquisition enables Boston Scientific to expand its chronic pain portfolio and strengthen its leadership in interventional pain management by providing innovative, FDA-cleared therapies that improve patient access and outcomes. Relievant Medsystems Inc. is a US-based company specializing in treatments for chronic low back pain, specifically targeting vertebrogenic pain.

Major companies operating in the bone pain treatment market are AbbVie Inc., Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Perrigo Company plc, Viatris Inc., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Indivior PLC, Pfizer Consumer Healthcare (Haleon), Kyowa Kirin Co. Ltd., Ferring Pharmaceuticals, Chiesi Farmaceutici S.p.A., Bausch Health Companies Inc., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co. Ltd., Fresenius Kabi, Aurobindo Pharma Ltd., Intas Pharmaceuticals Ltd.

North America was the largest region in the bone pain treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bone pain treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bone pain treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of pharmaceutical ingredients, pain management drugs, and surgical supplies used in the bone pain treatment market. Opioids, NSAIDs, and surgical intervention segments are most affected, particularly in Asia-Pacific and North America due to reliance on imported APIs and medical devices. However, tariffs are promoting local drug manufacturing and orthopedic equipment production, improving long-term treatment availability.

The bone pain treatment market research report is one of a series of new reports that provides bone pain treatment market statistics, including bone pain treatment industry global market size, regional shares, competitors with a bone pain treatment market share, detailed bone pain treatment market segments, market trends and opportunities, and any further data you may need to thrive in the bone pain treatment industry. This bone pain treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bone pain treatment refers to medical interventions aimed at relieving discomfort or aching in the bones caused by conditions such as fractures, infections, cancer, or chronic diseases. Treatments typically include medications, physical therapy, and, in some cases, surgical procedures to address the underlying cause and reduce pain.

The main types of bone pain treatment include pharmacological treatments, non-pharmacological treatments, and surgical interventions. Pharmacological treatments involve the use of drugs to prevent, manage, or treat medical conditions by targeting specific biological processes. Drug classes commonly used include analgesics, antidepressants, anticonvulsants, and corticosteroids. Bone pain treatments are indicated for conditions such as injuries, infections, myalgia, and tumors. These treatments are distributed through direct sales, retail pharmacies, and online pharmacies, serving end-users such as hospitals, clinics, and homecare settings.

The bone pain treatment market includes revenues earned by entities by providing services such as pharmacological therapy services, physical therapy and rehabilitation services, surgical intervention services, pain management clinics, and diagnostic imaging and evaluation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The bone pain treatment also includes sales of acetaminophen, ibuprofen, naproxen, morphine, oxycodone, alendronate, and prednisone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.